Why Non-Binary Hormone Therapy Is Different
Non-binary hormone therapy recognizes that not everyone wants or needs full masculinization or full feminization. Your gender is unique to you, and your hormone treatment should be too. Maybe you want a deeper voice but not facial hair. Maybe you want softer skin and some fat redistribution but not breast development. Maybe you want just enough change to feel more comfortable in your body without a dramatic transformation. Non-binary HRT is about finding the right balance for your goals — not fitting into a binary framework.
Your Goals Define the Plan
The first and most important step in non-binary HRT is defining what you want. Your provider should ask about your specific goals: what changes would make you feel more like yourself? What changes would you want to avoid? How much change are you comfortable with? The answers to these questions shape your treatment plan. There is no "standard" non-binary protocol because there is no "standard" non-binary experience.
What Is Possible and What Is Not
It is important to have realistic expectations. Hormones affect multiple body systems simultaneously — you cannot select individual changes like items from a menu. However, low-dose protocols slow the pace of change, giving you more control. And some selective approaches (like using finasteride with testosterone, or SERMs with estrogen) can modify which changes are more or less pronounced. Your provider will have an honest conversation about what is achievable.
Low-Dose Testosterone for Non-Binary People
Low-dose testosterone uses approximately one-quarter to one-half the standard masculinizing dose. This produces slower, more gradual changes that may better match non-binary goals for partial masculinization or a more androgynous appearance.
| Protocol | Dose | Expected Effect |
|---|---|---|
| Quarter dose SubQ | 12.5-25 mg/week | Very gradual changes; some voice deepening over months; minimal facial hair |
| Half dose SubQ (most common) | 25-40 mg/week | Moderate pace; voice deepening, some fat redistribution, gradual body hair |
| Low-dose gel | 12.5-25 mg/day | Steady, subtle changes; less fluctuation than injection |
What Low-Dose T Can Achieve
- Gradual voice deepening (still permanent but develops more slowly)
- Some fat redistribution toward a more androgynous pattern
- Increased energy and possibly libido
- Cessation of menstruation (may take longer than standard doses)
- Subtle body hair increases
- Mild clitoral growth
Important Considerations
- Permanent changes still occur — just more slowly. Voice deepening and facial hair growth are permanent even at low doses
- Individual variation is significant — some people see changes faster on low doses than others
- You can adjust over time — start low and increase or decrease based on how you feel
- Monitoring is still essential — hematocrit and other labs should be checked regularly
- Combining with finasteride can slow facial/body hair growth while allowing voice changes (discuss with provider)
Low-Dose Estrogen for Non-Binary People
Low-dose estrogen follows the same principle: slower, more gradual feminization that may better match non-binary goals for partial feminization or androgyny.
| Protocol | Dose | Expected Effect |
|---|---|---|
| Quarter dose oral | 0.5-1 mg/day | Very subtle changes; some skin softening; slow fat redistribution |
| Half dose oral/sublingual | 1-2 mg/day | Moderate pace; skin changes, some fat redistribution, possible breast budding |
| Low-dose patch | 25-50 mcg/day | Steady, gradual changes; safest route for DVT risk |
Some non-binary people want feminizing changes (softer skin, fat redistribution, emotional changes) but not breast development. Selective estrogen receptor modulators (SERMs) like raloxifene or tamoxifen can block estrogen's effects on breast tissue while allowing other feminizing changes to proceed. This is an off-label approach that requires careful provider guidance. Results vary — breast tissue prevention may not be complete — but this option represents the kind of individualized treatment that non-binary people deserve access to.
Selective and Combination Approaches
For non-binary people who want specific changes while minimizing others, several selective strategies are possible. These approaches are more experimental and require a knowledgeable provider.
Testosterone + Finasteride/Dutasteride
Goal: Voice deepening and fat redistribution while slowing facial/body hair growth and reducing hair loss risk.
Finasteride blocks the conversion of testosterone to DHT (dihydrotestosterone), which is responsible for facial hair growth, body hair growth, and male-pattern baldness. This combination can allow voice changes (which are driven by testosterone itself, not DHT) while reducing hair-related changes. Note: some DHT-driven changes like clitoral growth may also be reduced.
Estrogen + SERM (Raloxifene/Tamoxifen)
Goal: Feminizing changes without breast development.
SERMs selectively block estrogen receptors in breast tissue while acting as estrogen agonists in other tissues. This can allow skin softening, fat redistribution, and emotional changes while limiting breast growth. This is an off-label use, and breast prevention may not be complete. Close monitoring is required.
Temporary or Cyclical HRT
Goal: Achieve certain permanent changes, then stop.
Some non-binary people take hormones for a defined period to achieve specific permanent changes (like voice deepening on testosterone) and then discontinue. Reversible changes will revert, while permanent changes remain. This "pulse" approach requires clear communication with your provider about goals and realistic expectations about what each phase of treatment will achieve.
Anti-Androgen Only (No Added Hormones)
Goal: Reduce testosterone effects without adding estrogen.
Some non-binary AMAB individuals take anti-androgens alone to reduce masculine features (body hair, oiliness, muscle mass) without adding feminization. This approach requires careful monitoring because operating with low levels of both sex hormones can affect bone density, mood, and energy. A provider may recommend low-dose estrogen for bone health.
Microdosing HRT: What You Need to Know
Microdosing has become a popular term in the non-binary community. Here is what it means, how it works, and what to realistically expect.
What Microdosing Means
Microdosing HRT typically means taking approximately one-quarter to one-half the standard dose of testosterone or estrogen. The goal is not to avoid changes entirely — it is to slow the pace of change, allowing you to experience each change gradually and decide at each step whether you want to continue. Think of it as turning the dial slowly rather than flipping a switch.
What Microdosing Does NOT Mean
- It does NOT mean no changes will occur — changes still happen, just more slowly
- It does NOT prevent permanent changes — voice deepening on low-dose T is still permanent
- It does NOT mean you can select individual changes — all hormone-driven changes will eventually occur if you continue long enough
- It does NOT eliminate the need for monitoring — lab work is still essential
- It IS a valid approach that many non-binary people find empowering because it gives them more agency over the pace of their transition
WPATH SOC 8 Support for Non-Binary Care
The WPATH Standards of Care Version 8, published in 2022, explicitly supports individualized hormone therapy for non-binary people.
What SOC 8 Says
- Gender identity exists on a spectrum, and non-binary identities are valid and recognized
- Hormone therapy can be individualized to match each person's goals, including partial masculinization or feminization
- Low-dose protocols are appropriate when they align with a patient's treatment goals
- The informed consent model is supported for non-binary people, just as for binary transgender individuals
- Providers should be knowledgeable about non-binary-specific approaches and respectful of diverse gender experiences
Finding Non-Binary-Affirming Care
- Ask directly: "Do you have experience with non-binary hormone protocols?"
- Look for flexibility: Providers who are willing to discuss individualized goals rather than prescribing a one-size-fits-all protocol
- Informed consent providers: IC clinics are often more experienced with diverse transition goals
- Telehealth options: Hormone Pharma and other telehealth services serve non-binary patients with individualized care
- Community recommendations: Non-binary community groups and forums can recommend affirming providers
Frequently Asked Questions About Non-Binary Hormone Therapy
Absolutely. Hormone therapy is available to anyone who would benefit from it, regardless of where they fall on the gender spectrum. You do not need to identify as a binary trans man or trans woman to access HRT. WPATH Standards of Care Version 8 explicitly recognizes non-binary identities and supports individualized hormone therapy protocols. At Hormone Pharma, we welcome non-binary patients and work with you to create a treatment plan that reflects your unique goals.
Low-dose testosterone uses approximately one-quarter to one-half the standard masculinizing dose — typically 12.5-40 mg/week via subcutaneous injection or equivalent in gel form. Changes occur more slowly and gradually, giving you more time to evaluate each one. Voice deepening, fat redistribution, and cessation of menstruation still occur, but at a gentler pace. This approach is popular among non-binary individuals who want some masculinization while maintaining a more androgynous appearance.
Not entirely, because hormones affect multiple body systems at once. You cannot get voice deepening from testosterone without eventually getting some facial hair growth, for example. However, selective approaches can modify the balance: finasteride with testosterone can reduce hair growth while allowing voice changes; SERMs with estrogen can limit breast development while allowing other feminization. Low-dose protocols also give you more control by slowing the pace, letting you stop when you have reached the level of change that feels right.
Microdosing means taking hormones at a significantly lower dose than standard protocols — usually one-quarter to one-half the standard dose. The aim is not to prevent changes but to slow them down, giving you more agency over the pace of your transition. Changes still occur (including permanent ones), but they develop more gradually. This approach is embraced by many non-binary individuals who want subtle, incremental changes rather than rapid, full masculinization or feminization.
Selective estrogen receptor modulators (SERMs) like raloxifene and tamoxifen can block estrogen's effects on breast tissue while allowing other feminizing changes. This is an off-label approach that requires careful guidance from a knowledgeable provider. Results vary — breast tissue prevention may not be complete, and there are potential side effects to discuss. If this is important to you, raise it with your provider during your consultation.
Yes. Low-dose hormones produce the same types of changes as standard doses — they simply develop more slowly. Voice deepening on low-dose testosterone is still permanent. Breast development on low-dose estrogen is still permanent. The advantage of low dosing is the pace: you have more time to experience each change incrementally and decide whether you want to continue. If you reach a point where you are satisfied, you can stop or adjust your dose.
Yes. WPATH Standards of Care Version 8 explicitly recognizes non-binary identities and supports individualized hormone therapy protocols. The guidelines state that gender identity exists on a spectrum, that treatment goals vary among individuals, and that low-dose and selective approaches are legitimate. This represents significant progress in the medical community's understanding of gender diversity and the importance of person-centered care.
Look for providers who explicitly mention non-binary care, use the informed consent model, and are willing to discuss individualized treatment goals rather than offering a one-size-fits-all protocol. Telehealth services like Hormone Pharma serve non-binary patients with tailored care plans. Community recommendations from non-binary groups and forums can also point you toward affirming providers. During your consultation, ask about their experience with low-dose protocols and selective approaches.
Your Identity, Your Treatment Plan
We believe that your hormone therapy should be as unique as your identity. Connect with a provider who will listen and create a plan that is truly yours.
Start Your ConsultationReferences
- Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health. 2022;23(Suppl 1):S1-S259. PubMed
- Cocchetti C, Ristori J, Romani A, et al. Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals. J Clin Med. 2020;9(6):1609. PubMed
- Deutsch MB. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. UCSF Center of Excellence for Transgender Health. 2016.
- Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(11):3869-3903. PubMed
- Leinung MC, Urizar MF, Patel N, Sood SC. Endocrine treatment of transsexual persons: extensive personal experience. Endocr Pract. 2013;19(4):644-650. PubMed
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Non-binary hormone therapy should be prescribed and monitored by a qualified healthcare provider experienced in individualized gender-affirming care. Some approaches described (SERMs with estrogen, finasteride with testosterone) are off-label and require careful medical supervision. Always seek the guidance of your physician or other qualified health professional with any questions regarding your medical care. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.